U.S. Markets closed

Bask in Bright Biotech $ALKS $IBB


A total of five companies were identified, two small caps (less than $1 billion) and three mid caps (from $1 to $5 billion). The basis for these trades is biotechnology’s favorable season as detailed on page 92 of the Stock Trader’s Almanac 2013. All five recommendations will be tracked in their respective Almanac Investor Portfolios and will appear in the next update.

Alkermes (ALKS) is the final company of the day with a Magnet Score of 510. ALKS has retreated from its late May run of new 52-week highs. On a valuation basis, ALKS is the least attractive in this group. However, with a growth ratio over 300 and earnings growth even higher it is an attractive company. 

Disclosure Note: At press time, the Magnet AE Fund did not have a position in ALKS. Mr. Kimmel, Mr. Hirsch and the Magnet AE Fund may buy or sell securities mentioned in this article at any time.

Magnet® is a registered trademark of Jordan Kimmel. Jordan L. Kimmel is the Managing Member & Portfolio Manager of Magnet AE Management LLC and Jeffrey A. Hirsch is the Chief Market Strategist and a limited partner in the Magnet AE Fund.


This article has been prepared solely for informational purposes, and is not an offer to buy, nor sell or a solicitation of an offer to buy or sell any security, product, service or investment. The opinions expressed herein do not constitute investment advice and independent advice should be sought where appropriate. All information and opinions expressed herein are current as of publication and are subject to change without notice.

Investing involves substantial risk. Neither Mr. Hirsch, nor any of his respective affiliates, employees and/or associates makes any guarantee or other promise as to any results that may be obtained from using this information. The advice and strategies contained herein may not be suitable for every situation. While past performance may be analyzed in this presentation, past performance should not be considered indicative of future performance. No one should make any investment decision based on this information without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer. Neither Mr. Hirsch, nor any of his respective affiliates, employees and/or associates makes any representations or warranties with respect to the accuracy or completeness of the contents of the information herein and specifically disclaim all warranties, including without limitation warranties of fitness for a particular purpose. Neither Mr. Hirsch, nor any of his respective affiliates, employees and/or associates shall be liable for damages arising here from. No warranty is or may be construed to be created or extended by informational, sales or promotional materials.

Alkermes (ALKS) Daily Chart